Kornimate/medical-research-clean huggingface dataset:
nevoid basal cell carcinomas in gorlin syndrome

Conditions: Basal Cell Carcinoma; Gorlin Syndrome

Summary: the overall aim of the project is to gain knowledge about the expected course of nevoid basal cell carcinomas and the usefulness of dermatoscopy in young individuals with gorlin syndrome. clinical experience and some case-reports suggest that nevoid basal cell carcinomas have an indolent course with slow growth and that they can sometimes regress. however, no systematic research has previously been performed. increased knowledge about nevoid basal cell carcinomas and the use of dermatoscopy could be of great clinical value in the follow-up and treatment of individuals with nevoid basal cell carcinoma syndrome.


Eligibility criteria:
inclusion criteria: * the individual has gorlin syndrome (clinically and/or genetically diagnosed) * the individual is minimum 6 years and maximum 17 years * the individual has at least three skin lesions clinically compatible with nevoid basal cell carcinomas exclusion criteria: * the patient has a psychiatric disorder not compatible with completion of the study examinations * the patient has received topical treatment (imiquimod, 5-fluorouracil, photodynamic therapy and/or cryotherapy) of nevoid basal cell carcinomas during the last three months

Keywords: dermatoscopy
manual therapy for pregnancy related back pain

Conditions: Low Back Pain

Summary: more than 50% of women experience pain in the lumbopelvic area during pregnancy. the prevalence of pain increases with the duration of pregnancy. trunk muscles are needed to sustain low levels of activity for an extended duration. preventing muscles from fatiguing is very important. manual therapy techniques can minimize loading of the spine while improving muscular endurance and preventing fatigue. moreover, inhibition of the trigger points of the spinal musculature is an important factor to consider.

tui-na massage and positional release therapy are both of the common manual therapies used recently for low back pain. however, no studies have compared their effects on pregnancy related low back pain in third trimester.

Eligibility criteria:
inclusion criteria: * low back pain * mild to moderate disability concurring to the oswestry disability index (up to 40%), * age ranged from 20 - 40 years exclusion criteria: * current physical therapy or medical treatment for low back pain, * contracture or surgery affecting the lumbar spine, * scoliosis, * pathologies such as inflammatory diseases, * skin diseases, * congenital diseases, * neurological diseases, * dislocations, neoplasms, * disc prolapse, * visual or auditory problems

Keywords: manual therapy
clinical performance of one-shade universal dental resin composite as posterior restoration

Conditions: Carious Teeth

Summary: this study is aimed to evaluate the clinical performance of new one-shade universal composite resin as posterior restoration using us public health service "uspsh" criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months.

one operator will place all restorations under rubber-dam isolation. the patients will receive restorations with both materials, randomly after shade selection (the shade of single shade universal resin composite "omnichroma" will be taken before and after placement into the cavity). during the referred period, only the two composites in study will be placed in posterior teeth in the dental office. the various materials' application procedure will be applied according to manufacturer's instructions.

Eligibility criteria:
inclusion criteria: * • they should have an acceptable oral hygiene level. * presence of at least two occlusal carious lesions to be restored with two different types of composite. * the two studied materials restorations should be used in approximately the same sized lesions or within the same extension. * age range between 25 and 45years. exclusion criteria: * • severe or active periodontal or carious disease and heavy bruxism or a traumatic occlusion * patients with a compromised medical history, or had received therapeutic irradiation to the head and neck region. * alcoholic and smoker patients. * patients had participated in a clinical trial within 6 months before commencement of this trial. * patients unable to return for recall appointment
phase ii randomized, double-blind, placebo-controlled study of bms-188667 (ctla4ig) in patients with psoriasis vulgaris

Conditions: Psoriasis Vulgaris

Summary: the purpose of this study is to assess the safety, pharmacokinetics and clinical activity and immunogenicity of bms-188667 (ctla4ig) in subjects with psoriasis vulgaris


Eligibility criteria:
inclusion criteria: * diagnosis and documentation of a history of stable psoriasis vulgaris of at least 6 months duration. * vulgaris total body surfae area involvement of at least 10% * failure for toxicity and/or inefficacy of at least one standard anti- psoriatic therapy including topical treatment, phototherapy, photochemotherapy, methotrexate, cyclosporin a or etretinate. exclusion criteria: * male and female subjects who are not willing to receive adequate counseling and exercise adequate contraceptive measures with enrolle on study. * functional class (v (acr) ra or amyloidosis) * active vasculitis (except for subcutaneous rheumatoid nodules). * subjects with a history of asthma, angioedema or anaphylaxis. * subjects with evidence of active or latent bacterial or viral invedtions. * subjects with a history or malignancy (except basal cell or superficial squamous cell skin carcinoma). * body weight \> 100 kg (or 220 lbs.)
islatravir (mk-8591) with doravirine and lamivudine in participants infected with human immunodeficiency virus type 1 (mk-8591-011)

Conditions: HIV-1 Infection

Summary: this study will evaluate the safety, tolerability, antiretroviral activity, and pharmacokinetics of 3 doses of islatravir (mk-8591) in combination with doravirine (dor) and lamivudine (3tc) administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (hiv-1) infection.


Eligibility criteria:
inclusion criteria: * has hiv-1 infection * is naïve to anti-retroviral therapy (art). * is clinically stable, with no signs or symptoms of acute infection, at the time of entry into the study * female is not pregnant, not breastfeeding, not a woman of childbearing potential (wocbp); but if wocbp agrees to follow the contraceptive guidance * all participants, male and female, agree to use barrier methods of contraception when engaged in any sexual activity during treatment and for 6 weeks following treatment. exclusion criteria: * is a user of recreational or illicit drugs or has had a history of drug or alcohol abuse or dependence that may interfere with trial participation * has significant hypersensitivity or other contraindication to any of the components of the study drugs * has a history of malignancy ≤5 years prior * female expects to donate eggs at any time during the study * is breastfeeding or expecting to conceive * a wocbp who has a positive urine pregnancy test on day 1 before the first dose of study treatment * has been treated for a viral infection other than hiv-1, such as hepatitis b, with an agent that is active against hiv-1 * has used systemic immunosuppressive therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study * requires any of the following prohibited medications: carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, herbal remedies, st. john's wort, modafinil, bosentan, nafcillin, pentostatin * is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days of signing informed consent to participate in this current trial * has a documented or known virologic resistance to any approved hiv-1 reverse transcriptase inhibitor, protease inhibitor, integrase inhibitor * has active hepatitis c virus (hcv) coinfection defined as detectable hcv rna or hbv co-infection defined as hepatitis b surface antigen \[hbsag\]-positive * has a current (active) diagnosis of acute hepatitis due to any cause * has previously been randomized in a study and received islatravir (mk-8591), dor, doravirine, tenofovir, lamivudine, or 3tc.
the impact of frailty on thrombosis of elderly patients with nvaf （fte-nvaf）

Conditions: Non-valvular Atrial Fibrillation, Elderly, Frailty, Thrombosis

Summary: this study aims to investigate the use of anticoagulants in elderly patients with non-valvular atrial fibrillation (nvaf) and the incidence of frailty in elderly patients with nvaf. after two years follow-up, we observe the incidence of thrombotic events and the influence of frailty on thrombotic events in elderly patients with nvaf.


Eligibility criteria:
inclusion criteria: * ≥65yr * confirmed non-valvular atrial fibrillation (nvaf) diagnosis with ecg or holter * fulfilled cha2ds2-vasc, has-bled and fried scale * patients agreed and provided informed consent exclusion criteria: * valvular atrial fibrillation * cardiac surgery related atrial fibrillation * acute disease related atrial fibrillation * patients not fulfilled all the exam and text，or not accept the follow-up
endoscopic characterization of colorectal neoplasia with the different published classifications: a prospective comparative study

Conditions: ENDOSCOPIC CHARACTERIZATION

Summary: endoscopic characterization of colorectal lesions has become essential to predict histology and choose the best therapeutic strategy. we have created the conecct classification grouping all the endoscopic criteria already published in a single table. to validate this classification, we carried out this comparative study evaluating the endoscopic characterization performance of all recognized classifications and conecct in terms of inter-observer agreement and histological prediction.


Eligibility criteria:
inclusion criteria: * none exclusion criteria: * none
evlwi exhibits pulmonary and systemic permeability in sepsis related ali/ards

Conditions: Sepsis Related Acute Lung Injury/Acute Respiratory Distress Syndrome

Summary: to investigate the possible mechanisms of pulmonary and systemic permeability change including cytokine, extravascular lung water index (evlwi), and oxygenation parameters in patients with sepsis related acute lung injury (ali)/acute respiratory distress syndrome (ards).

this investigation is a prospective control study. informed consents will be obtained from all patients or their surrogates prior to the procedure of evlwi measurement and blood sampling for molecular measurement including cytokines. from july 2011 to june 2014, consecutive septic patients with ards in intensive care units (icus) will be enrolled at chang gung memorial hospital, a university-affiliated hospital in taiwan. evlwi will be measured by picco monitoring system. serum cytokine such as endothelin-1, tnf-alfa, il-6, tie-1, tie-2, angiopoietin-1, angiopoietin-2,vegf and thrombomodulin will be measured.

Eligibility criteria:
inclusion criteria: * sepsis in icu within 48 hours, * mechanical ventilator use, * pao2/fio2 \< 300, exclusion criteria: * age younger than 20 years, * known pregnancy, * participation in another trial within 30 days before meeting the eligibility criteria, and * terminal malignancy.

Keywords: relationship endothelial injury vascular permeability severe sepsis related ali/ards
temozolomide, nedaplatin, vincristine, and radiotherapy as first-line treatment in newly diagnosed primary cns lymphoma

Conditions: Central Nervous System Tumors

Summary: in this trial, we will treat newly diagnosed pcnsl with temozolomide, nedaplatin, vincristine (tnv) as the replacement of high-dose methotrexate to combine with concurrent chemoradiotherapy. our objective was to assess our treatment strategies' availability based on response rates, progression-free survival (pfs), median pfs, and toxicity.

the best reported outcomes of pcnsl treatment are high-dose methotrexate-based chemotherapy combined with whole-brain radiation therapy (wbrt). despite aggressive therapy, however, nearly 50% of patients will relapse within 24 months of diagnosis. furthermore, the application of high-dose methotrexate-based regimen is complex, needing be hydrated, alkalified and detoxified, and treatment-related toxicity mortality is severe\[3,4\]. in an attempt to improve upon these poor results and reduce treatment-related side effects, we will treat about 15-20 pcnsl patients with temozolomide concurrent chemoradiotherapy at the outset and then adjuvant chemotherapy for 6 cycles with temozolomide, nedaplatin, vincristine, as part of front-line therapy. our objective is to assess our treatment strategies' availability based on response rates, progression-free survival (pfs), median pfs, and toxicity.

Eligibility criteria:
inclusion criteria: * histologically confirmed primary cns lymphoma. * newly diagnosed. * ecog (eastern cooperative oncology group) performance status of 0-1. * relevant hospital examination including laboratory examination and physical examination (chest x-ray, electrocardiogram, abdomen b ultrasonography, magnetic resonance imaging (mri) of head and neck) must to be done, in order to exclude other system fatal diseases. * must have adequate organ function as defined by the protocol: adequate renal function: serum creatinine ≤ 1.5 mg/dl and/or calculated creatinine clearance ≥ 60 ml/min; adequate hepatic function: bilirubin level ≤ 1.5 x uln, asat \& alst ≤ 1.5 x uln.adequate bone marrow reserves: neutrophil (anc) count ≥ 1500 /mm\^3, platelet count ≥ 100,000 /mm\^3, hemoglobin ≥ 9 g/dl. * age \>/= 18 and \</= 75 years * signed written informed consent prior to study entry. exclusion criteria: * patients with human immunodeficiency virus seropositivity and systemic lymphoma manifestation. * serious uncontrolled concurrent illness. * previous brain radiotherapy, systemic chemotherapy. * concurrent chronic systemic immune therapy, targeted therapy not indicated in this study protocol. * any evidence of prior exposure to hepatitis b virus. * unable to comprehend the study requirements or who are not likely to comply with the study parameters. * pregnant (confirmed by serum or urine β-hcg) or lactating.

Keywords: lymphoma
autologous platelet rich plasma on low back pain

Conditions: Low Back Pain

Summary: the purpose of this study is to evaluate the effectiveness of autologous platelet-rich plasma (prp) injection therapy for low back pain patients. our hypothesis is that prp will reduce the pain feeling and benefit for restore of the intervertebral disk.


Eligibility criteria:
inclusion criteria: * chronic low back pain more than 2months * visual analog scale score more than 4 * positive x-ray, mri or ct scan findings * pfirrmann grading i-iii * well understanding and communication ability exclusion criteria: * history of allergy * hemorrhagic trend or use of anticoagulant therapy * mental diseases * active infection or recent infectious diseases within 3 months * local skin infection near the puncture location * severe lumbar spinal stenosis, lumbar spondylolisthesis, ossification of posterior longitudinal * ligament and lumbar disc herniation（more than 5mm） * immunologic diseases * tumors * metastatic disease * recent surgery less than 3 months) * pregnancy

Keywords: platelet rich plasma intervertebral disk injection therapy low back pain ultrasound guided degenerative spinal disease
a trial of shr-a2102 with antitumor therapy in advanced urothelial carcinoma

Conditions: Advanced Urothelial Carcinoma

Summary: the study is being conducted to evaluate the safety, tolerability and efficacy of shr-a2102 for injection with antitumor therapy in advanced urothelial carcinoma. to explore the reasonable dosage of shr-a2102 for advanced urothelial carcinoma.


Eligibility criteria:
inclusion criteria: 1. competent to comprehend, sign, and date an informed consent form. 2. male or female subjects must be age 18 or older. 3. eastern cooperative oncology group (ecog) performance status of 0 or 1. 4. subjects must have histologically documented, unresectable locally advanced or 5. histologically confirmed locally advanced or metastatic urothelial cancer.phase ib, subjects must have failed, be intolerant or refused the standard treatment; phase ii, subjects must not have received systemic antitumor therapy for locally advanced unresectable or metastatic urothelial carcinoma. 6. an archival tumor tissue sample or a fresh tissue sample should be provided. 7. subjects must have measurable disease according to recist (version 1.1). exclusion criteria: 1. subjects with not adequately treated, or uncontrollable , or active cns metastases. 2. subjects who have previously received topo1-based adcs. 3. subjects who have received anti-cancer treatment within 4 weeks prior the first dose of study treatment. 4. subjects who have received radiotherapy within 14 days , or chest radiotherapy \> 30gy within 6 months prior to the first dose of study drug. 5. subjects with ongoing clinically significant toxicity associated with prior treatment that has not resolved to ≤ grade 1. 6. subjects who have received systemic immunosuppressant treatment within 14 days prior the first dose of study treatment. 7. subjects who have known or suspected interstitial pneumonitis. 8. phase ib: subjects who have had≥ grade 3 iraes during the previous treatment with icis. 9. subjects who have any active, known or suspected autoimmune diseases. 10. subjects who have moderate or severe ascites with clinical symptoms, or uncontrolled or moderate or above pleural effusion, or pericardial effusion. 11. subjects who have uncontrolled cardiac diseases or cardiac clinical symptoms.
buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: ctn 0075

Conditions: Opioid Use Disorder

Summary: this pilot study examines the feasibility and acceptability of transitioning office-based buprenorphine treatment of opioid use disorder from physicians to pharmacists. results from this study will inform the development of a future multi-site randomized clinical trial.

the overall objective of this study is to explore the feasibility of transitioning the care of adult patients with opioid use disorder (oud) who receive office-based buprenorphine treatment (obbt) from physicians to pharmacists. physicians will induce buprenorphine treatment and complete the stabilization phase before referring patients to pharmacists for the management of monthly maintenance visits. this study will assess the feasibility and acceptability of a collaborative care model between physician and pharmacist by measuring recruitment rate, treatment retention rate, treatment compliance rate, and participants' substance use. other assessments measured will include treatment fidelity, participant, physician, and pharmacist satisfaction with oud care, participant safety, and the pharmacists' use of electronic health records and the prescription drug monitoring program.

Eligibility criteria:
inclusion criteria: * be adults aged 18 years or older. * if female, use adequate birth control methods. * meet dsm-5 criteria for past-year oud and have completed buprenorphine induction for oud. * have expressed the intention to receive maintenance (≥6 months) buprenorphine treatment. * be willing to receive pharmacist administered buprenorphine maintenance treatment * be willing and able to provide written informed consent and hipaa authorization. * be able to read and communicate in english. * be able to comply with buprenorphine treatment policies. exclusion criteria: * have a serious medical, psychiatric or substance use disorder that, in the opinion of the study physician, would make study participation hazardous to the participant, compromise study findings, or prevent the participant from completing the study. * have known allergy or hypersensitivity to buprenorphine, naloxone, or other components of the buprenorphine/naloxone formulation. * have aspartate aminotransferase (ast) or alanine aminotransferase (alt) liver enzymes greater than 5 times the upper limit of normal on screening phlebotomy performed within 60 days prior to the date of the last stabilization visit. * have chronic pain requiring ongoing pain management with opioid analgesics. * pending legal action or other reasons that might prevent an individual from completing the study (i.e., unable to complete 6 months of pharmacy-based oud management). * pregnant or breastfeeding at the time of screening.

Keywords: opioid use disorder medication-assisted treatment buprenorphine treatment collaborative care model
effect of brain training through visual mirror feedback, action observation training and motor imagery on orofacial sensorimotor variables in asymptomatic subjects: a single-blind randomized controlled trial.

Conditions: Exercise; Pain

Summary: the main objective of the present study was to evaluate the effects of action observation (ao), visual mirror feedback (vmf), motor imagery (mi) combined with an orofacial exercise program in asymptomatic subjects.


Eligibility criteria:
inclusion criteria: 1. healthy individuals with no pain 2. aged between 18 and 65 years 3. subjects with correct masticatory function and labial and lingual mobility exclusion criteria: 1. individuals who presented systemic, cardiorespiratory, central nervous system or rheumatic diseases, or those who presented any musculoskeletal or craniocervical pathology 2. underage individuals 3. individuals with orofacial pain or temporomandibular disorders at the time of the study; (d) subjects' complaint of toothache or tenderness to percussion.

Keywords: motor imagery action observation visual mirror feedback pain pressure thresholds
depression and pain perseverance through empowered recovery intervention

Conditions: Pain; Depressive Symptoms; Frailty; Aging

Summary: african american women who are 50 years of age and older with depressive symptoms, pain and difficulty with mobility will participate in the dapper intervention study that includes 8 nurse visits in participants' homes to help participants with participants' pain and mood.

the proposed intervention is called depression and pain perseverance through empowered recovery (dapper). the investigators are adapting the get busy get better intervention by adding components (e.g. nurse visits and person directed goals) from the capable study for this intervention. the investigator will further develop the intervention through this two-phase pilot test. the aims of this pilot project are to 1) test the depression and pain perseverance through empowered recovery (dapper) program for feasibility and acceptability. specifically, the investigators will test the effect size of dapper on pain and depressive symptoms from baseline to 12 weeks (compare intervention to wait list control group) and then at 24 weeks to compare the intervention group to wait list control group once again. 2) estimate preliminary effect sizes for dapper in reduction pain and depressive symptoms, 3) measure effect sizes and feasibility of measuring cytokines and heart rate variability (hrv).

Eligibility criteria:
inclusion criteria: * self-report pain \>3 out of a 0 -10 scale that has lasted longer than 3 months and keeps subjects from doing at least one activity that subjects would like to do * self-identify as african american/black female * live in a community dwelling * score a 5 or higher on the phq-9 (depression measure) at least two times during a two week period (screening call and then at first data collection visit) * must be pre-frail (one or two criteria on frailty phenotype) or frail (three or more of the criteria on frailty phenotype) * one adl or iadl limitation exclusion criteria: * hospitalized \> 3 times in the last year * participating in physical therapy * have a terminal diagnosis (\<1 year expected survival) * \> moderate intellectual impairment (5-7 errors) based on the short portable mental status questionnaire (spmsq) * unable to speak or understand english

Keywords: african american women's health